Company intelligence / Profile preview
Virtuoso Therapeutics
San Mateo, California, USAvirtuosotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Virtuoso Therapeutics is advancing a pipeline of novel bispecific antibodies for oncology indications. Their lead program targets CD38 x ICAM‑1 for hematologic malignancies and has reached early clinical development. Other programs targeting the CD47 axis are in preclinical stages. The company aims to address limitations of current therapies by improving potency, selectivity, and therapeutic window through its proprietary technology platform. No published late-stage or commercial results as of now[2][3][5].
- Therapeutic areas
- HematologyOncology
- Modalities
- Bispecific antibodiesAntibody drug conjugates (ADC)Biological products[3][6]
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Virtuoso Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Virtuoso Therapeutics.